


BMO ARK Genomic Revolution Fund ETF Series (NEOE:ARKG)

Benchmark -


Printed on June 18, 2025

Performance Analysis

May 31, 2025




*Simulated performance since inception on November 15, 2022



Portfolio Allocations

March 31, 2025

Asset Allocations



Sector Allocations

Defensive	92.2%
Health Care	90.2%
Cash & Equivalent	2.0%
Sensitive	7.8%
Technology	6.2%
Industrial Goods	1.6%

Top Holdings

Top Holdings	% Assets
Twist Bioscience Corp - Common	8.88%
Tempus AI Inc - Common Cl A	8.18%
CRISPR Therapeutics AG - Common	7.15%
Reursion Pharmaceuticals Inc - Common Cl A	7.00%
Guardant Health Inc - Common	5.85%
Natera Inc - Common	5.65%
Adaptive Biotechnologies Corp - Common	5.64%
Schrodinger Inc - Common	4.43%
CareDx Inc - Common	4.33%
Beam Therapeutics Inc - Common	3.98%
Total percentage of top 10 holdings	61.09%
Total number of holdings	34

Investment Objective

This fund's objective is to provide long-term capital growth by investing primarily in equity securities of companies involved in disruptive genomic innovation from around the world.

Statistics

May 31, 2025

	ETF	Benchmark
Annualized Standard Dev	34.2%	-
Fixed Income	ETF	Benchmark
YTM	-	-
Credit Quality	-	-
Average Maturity	-	-

Risk Rating

May 31, 2025

Low	Low to Medium	Medium	Medium to High	High
-----	---------------	--------	----------------	------

The chart above shows the volatility level of the ETF (based on standard deviation of the ETF's total returns since inception).